Company

News Releases

Summer AAD Panel to Discuss BPX-01 for Acne and Rosacea

Jul 27, 2017

MENLO PARK, Calif., July 27, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that a panel of prominent dermatologists will discuss BPX-01, a unique topical hydrophilic gel formulation of minocycline at the 2017 AAD Summer Meeting tomorrow. BPX-01 is an investigational drug for the treatment of acne and rosacea.

 (PRNewsfoto/BioPharmX Corporation)

The discussion will take place during a three hour-long "Acne and Rosacea Session" at 1 p.m. Eastern, at the New York Hilton Midtown. Dermatologists involved in the panel include Dr. James Del Rosso, a board-certified dermatologist and researcher who is a member of the BioPharmX Dermatology Medical Advisory Board; Dr. Andrew Alexis, chairman of the Department of Dermatology at Mount Sinai St. Luke's and Mount Sinai West in New York City, and Dr. Linda Stein Gold, director of Dermatology Clinical Research at Henry Ford Health System in Detroit.

Phase 2b data found BPX-01 reduced acne lesions by 59%, delivered at least a two-grade reduction to clear or almost clear in investigator global assessments for 25% of subjects and was generally well tolerated, without any serious drug-related adverse events, photosensitivity, staining or skin discoloration. A survey of study participants found 86% would use BPX-01 again and 79% said the drug  was easy to use and apply.

"The dermatology community is excited about these promising clinical results," said Hilary E. Baldwin, MD, Clinical Associate Professor, Rutgers Robert Wood Johnson Medical Center, Medical Director, Acne Treatment & Research Center and Co-Chair of BioPharmX Medical Advisory Board, "There has been little innovation in acne treatment for several decades. BPX-01 could lead to significant change in the standard of care."

The company is currently conducting an open-label phase 2 feasibility study for rosacea and continues making progress towards the next phase in trials for acne vulgaris.

The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting up to 50 million Americans. The disease can cause permanent scarring, low self-esteem, depression and anxiety.

About BioPharmX® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, and the commencement of future trials of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.

These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and quarterly report on Form 10-Q for the period ended April 30, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX is a registered trademark of BioPharmX, Inc.

 

SOURCE BioPharmX Corporation

For further information: Nina Brauer, nbrauer@biopharmx.com (650) 889-5030; Jim Martinez, jim@rightstorygroup.com (312) 543-9026


print email rss